Macrophages participate in host protection and the disease pathology associated with Leishmania braziliensis infection

BMC Infectious Diseases

Volumn 12, Issue , 2012, Pages

  Giudice, Angela ^a   Vendrame, Célia ^a   Bezerra, Caroline ^a   Carvalho, Lucas P ^a   Delavechia, Thaís ^a   Carvalho, Edgar M ^a,b   Bacellar, Olívia ^a,b  

^a FEDERAL UNIVERSITY OF BAHIA   (Brazil)

^b Instituto Nacional de Ciência e Tecnologia de Doenças Tropicais INCT DT CNPq MCT   (Brazil)

Author keywords

Chemokines; L. braziliensis; Macrophages; Subclinical infection

Indexed keywords

CHEMOKINE; CYTOKINE; NITRIC OXIDE; SUPEROXIDE; TUMOR NECROSIS FACTOR ALPHA;

AMASTIGOTE; ARTICLE; CELL CULTURE; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; HOST PARASITE INTERACTION; HUMAN; HUMAN CELL; INFECTION CONTROL; INFECTION RATE; INFECTION SENSITIVITY; LEISHMANIA BRAZILIENSIS; LEISHMANIASIS; MACROPHAGE; MUCOSAL LEISHMANIASIS; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; SKIN LEISHMANIASIS; SUPERNATANT; T LYMPHOCYTE ACTIVATION; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; PARASITOLOGY; PATHOGENICITY; PATHOLOGY; SECRETION; T LYMPHOCYTE;

CELLS, CULTURED; CHEMOKINES; HUMANS; LEISHMANIA BRAZILIENSIS; LEISHMANIASIS, CUTANEOUS; LYMPHOCYTE ACTIVATION; MACROPHAGES; NITRIC OXIDE; SUPEROXIDES; T-LYMPHOCYTES;

EID: 84858957169     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-12-75     Document Type: Article

References (41)

1. Bittencourt AL, Barral A. Evaluation of the histopathological classifications of American cutaneous and mucocutaneous leishmaniasis. Mem Inst Oswaldo Cruz 1991, 86(1):51-56. 10.1590/S0074-02761991000100009, 1845248.
2. Marsden PD, Jones TC. Clinical manifestations, diagnosis and treatment of leishmaniasis 1985, Amsterdam: Elsevier Science Publisher.
3. Ben Salah A, Louzir H, Chlif S, Mokni M, Zaatour A, Raouene M, Ismail RB, Dellagi K. The predictive validity of naturally acquired delayed-type hypersensitivity to leishmanin in resistance to Leishmania major-associated cutaneous leishmaniasis. J Infect Dis 2005, 192(11):1981-1987. 10.1086/498042, 16267771.
4. Bittar RC, Nogueira RS, Vieira-Goncalves R, Pinho-Ribeiro V, Mattos MS, Oliveira-Neto MP, Coutinho SG, Da-Cruz AM. T-cell responses associated with resistance to Leishmania infection in individuals from endemic areas for Leishmania (Viannia) braziliensis. Mem Inst Oswaldo Cruz 2007, 102(5):625-630. 10.1590/S0074-02762007005000069, 17710308.
5. Follador I, Araujo C, Orge G, Cheng LH, de Carvalho LP, Bacellar O, Almeida RP, Carvalho EM. Immune responses to an inactive vaccine against American cutaneous leishmaniasis together with granulocyte-macrophage colony-stimulating factor. Vaccine 2002, 20(9-10):1365-1368. 10.1016/S0264-410X(01)00469-8, 11818154.
6. Trujillo CM, Robledo SM, Franco JL, Velez ID, Erb KJ, Patino PJ. Endemically exposed asymptomatic individuals show no increase in the specific Leishmania (Viannia) panamensis-Th1 immune response in comparison to patients with localized cutaneous leishmaniasis. Parasite Immunol 2002, 24(9-10):455-462. 10.1046/j.1365-3024.2002.00488.x, 12654087.
7. Bacellar O, Lessa H, Schriefer A, Machado P, Ribeiro De Jesus A, Dutra WO, Gollob KJ, Carvalho EM. Up-regulation of Th1-type responses in mucosal leishmaniasis patients. Infect Immun 2002, 70(12):6734-6740. 10.1128/IAI.70.12.6734-6740.2002, 132996, 12438348.
8. Carvalho LP, Passos S, Bacellar O, Lessa M, Almeida RP, Magalhaes A, Dutra WO, Gollob KJ, Machado P, de Jesus AR. Differential immune regulation of activated T cells between cutaneous and mucosal leishmaniasis as a model for pathogenesis. Parasite Immunol 2007, 29(5):251-258. 10.1111/j.1365-3024.2007.00940.x, 2593461, 17430548.
9. Carvalho EM, Johnson WD, Barreto E, Marsden PD, Costa JL, Reed S, Rocha H. Cell mediated immunity in American cutaneous and mucosal leishmaniasis. J Immunol 1985, 135(6):4144-4148.
10. Follador I, Araujo C, Bacellar O, Araujo CB, Carvalho LP, Almeida RP, Carvalho EM. Epidemiologic and immunologic findings for the subclinical form of Leishmania braziliensis infection. Clin Infect Dis 2002, 34(11):E54-E58. 10.1086/340261, 12015707.
11. Ritter U, Korner H. Divergent expression of inflammatory dermal chemokines in cutaneous leishmaniasis. Parasite Immunol 2002, 24(6):295-301. 10.1046/j.1365-3024.2002.00467.x, 12102714.
12. Brandonisio O, Panaro MA, Fumarola I, Sisto M, Leogrande D, Acquafredda A, Spinelli R, Mitolo V. Macrophage chemotactic protein-1 and macrophage inflammatory protein-1 alpha induce nitric oxide release and enhance parasite killing in Leishmania infantum-infected human macrophages. Clin Exp Med 2002, 2(3):125-129. 10.1007/s102380200017, 12447609.
13. Faria DR, Gollob KJ, Barbosa J, Schriefer A, Machado PR, Lessa H, Carvalho LP, Romano-Silva MA, de Jesus AR, Carvalho EM, et al. Decreased in situ expression of interleukin-10 receptor is correlated with the exacerbated inflammatory and cytotoxic responses observed in mucosal leishmaniasis. Infect Immun 2005, 73(12):7853-7859. 10.1128/IAI.73.12.7853-7859.2005, 1307048, 16299275.
14. Assreuy J, Cunha FQ, Epperlein M, Noronha-Dutra A, O'Donnell CA, Liew FY, Moncada S. Production of nitric oxide and superoxide by activated macrophages and killing of Leishmania major. Eur J Immunol 1994, 24(3):672-676. 10.1002/eji.1830240328, 8125136.
15. Evans TG, Thai L, Granger DL, Hibbs JB. Effect of in vivo inhibition of nitric oxide production in murine leishmaniasis. J Immunol 1993, 151(2):907-915.
16. Murray HW, Teitelbaum RF. L-arginine-dependent reactive nitrogen intermediates and the antimicrobial effect of activated human mononuclear phagocytes. J Infect Dis 1992, 165(3):513-517. 10.1093/infdis/165.3.513, 1538156.
17. Cupolillo E, Grimaldi G, Momen H. A general classification of New World Leishmania using numerical zymotaxonomy. Am J Trop Med Hyg 1994, 50(3):296-311.
18. Reed SG, Badaro R, Masur H, Carvalho EM, Lorenco R, Lisboa A, Teixeira R, Johnson WD, Jones TC. Selection of a skin test antigen for American visceral leishmaniasis. Am J Trop Med Hyg 1986, 35(1):79-85.
19. Ding AH, Nathan CF. The measurement of cytochrome b559 in polymorphonuclear leukocytes and macrophages in the presence of hemoglobin or mitochondrial cytochromes. Anal Biochem 1988, 175(1):22-29. 10.1016/0003-2697(88)90355-7, 3245568.
20. Elstner EF, Heupel A. Inhibition of nitrite formation from hydroxylammoniumchloride: a simple assay for superoxide dismutase. Anal Biochem 1976, 70(2):616-620. 10.1016/0003-2697(76)90488-7, 817618.
21. Khouri R, Bafica A, Silva Mda P, Noronha A, Kolb JP, Wietzerbin J, Barral A, Barral-Netto M, Van Weyenbergh J. IFN-beta impairs superoxide-dependent parasite killing in human macrophages: evidence for a deleterious role of SOD1 in cutaneous leishmaniasis. J Immunol 2009, 182(4):2525-2531. 10.4049/jimmunol.0802860, 19201909.
22. Ribeiro-de-Jesus A, Almeida RP, Lessa H, Bacellar O, Carvalho EM. Cytokine profile and pathology in human leishmaniasis. Braz J Med Biol Res 1998, 31(1):143-148. 10.1590/S0100-879X1998000100020, 9686192.
23. Bosque F, Saravia NG, Valderrama L, Milon G. Distinct innate and acquired immune responses to Leishmania in putative susceptible and resistant human populations endemically exposed to L. (Viannia) panamensis infection. Scand J Immunol 2000, 51(5):533-541. 10.1046/j.1365-3083.2000.00724.x, 10792848.
24. Liew FY, Cox FE. Nonspecific defence mechanism: the role of nitric oxide. Immunol Today 1991, 12(3):A17-A21. 10.1016/S0167-5699(05)80006-4, 1712593.
25. Novais FO, Santiago RC, Bafica A, Khouri R, Afonso L, Borges VM, Brodskyn C, Barral-Netto M, Barral A, de Oliveira CI. Neutrophils and macrophages cooperate in host resistance against Leishmania braziliensis infection. J Immunol 2009, 183(12):8088-8098. 10.4049/jimmunol.0803720, 19923470.
26. Giudice A, Camada I, Leopoldo PT, Pereira JM, Riley LW, Wilson ME, Ho JL, de Jesus AR, Carvalho EM, Almeida RP. Resistance of Leishmania (Leishmania) amazonensis and Leishmania (Viannia) braziliensis to nitric oxide correlates with disease severity in Tegumentary Leishmaniasis. BMC Infect Dis 2007, 7:7. 10.1186/1471-2334-7-7, 1810296, 17316450.
27. Linares E, Augusto O, Barao SC, Giorgio S. Leishmania amazonensis infection does not inhibit systemic nitric oxide levels elicited by lipopolysaccharide in vivo. J Parasitol 2000, 86(1):78-82.
28. Van Assche T, Deschacht M, da Luz RA, Maes L, Cos P. Leishmania-macrophage interactions: insights into the redox biology. Free Radic Biol Med 2011, 51(2):337-351. 10.1016/j.freeradbiomed.2011.05.011, 21620959.
29. Afonso L, Borges VM, Cruz H, Ribeiro-Gomes FL, DosReis GA, Dutra AN, Clarencio J, de Oliveira CI, Barral A, Barral-Netto M, et al. Interactions with apoptotic but not with necrotic neutrophils increase parasite burden in human macrophages infected with Leishmania amazonensis. J Leukoc Biol 2008, 84(2):389-396. 10.1189/jlb.0108018, 18483206.
30. Campanelli AP, Brodskyn CI, Boaventura V, Silva C, Roselino AM, Costa J, Saldanha AC, de Freitas LA, de Oliveira CI, Barral-Netto M, et al. Chemokines and chemokine receptors coordinate the inflammatory immune response in human cutaneous leishmaniasis. Hum Immunol 2010, 71(12):1220-1227. 10.1016/j.humimm.2010.09.002, 20854864.
31. Guerreiro JB, Santos SB, Morgan DJ, Porto AF, Muniz AL, Ho JL, Teixeira AL, Teixeira MM, Carvalho EM. Levels of serum chemokines discriminate clinical myelopathy associated with human T lymphotropic virus type 1 (HTLV-1)/tropical spastic paraparesis (HAM/TSP) disease from HTLV-1 carrier state. Clin Exp Immunol 2006, 145(2):296-301. 10.1111/j.1365-2249.2006.03150.x, 1809672, 16879249.
32. Trebst C, Ransohoff RM. Investigating chemokines and chemokine receptors in patients with multiple sclerosis: opportunities and challenges. Arch Neurol 2001, 58(12):1975-1980. 10.1001/archneur.58.12.1975, 11735771.
33. Kanaly ST, Nashleanas M, Hondowicz B, Scott P. TNF receptor p55 is required for elimination of inflammatory cells following control of intracellular pathogens. J Immunol 1999, 163(7):3883-3889.
34. Pizzorni C, Secchi ME, Cutolo M. Leishmaniasis in rheumatoid arthritis. Reumatismo 2007, 59(3):235-239.
35. Antonelli LR, Dutra WO, Almeida RP, Bacellar O, Carvalho EM, Gollob KJ. Activated inflammatory T cells correlate with lesion size in human cutaneous leishmaniasis. Immunol Lett 2005, 101(2):226-230. 10.1016/j.imlet.2005.06.004, 16083969.
36. Da-Cruz AM, de Oliveira MP, De Luca PM, Mendonca SC, Coutinho SG. Tumor necrosis factor-alpha in human american tegumentary leishmaniasis. Mem Inst Oswaldo Cruz 1996, 91(2):225-229. 10.1590/S0074-02761996000200019, 8736095.
37. Bafica A, Oliveira F, Freitas LA, Nascimento EG, Barral A. American cutaneous leishmaniasis unresponsive to antimonial drugs: successful treatment using combination of N-methilglucamine antimoniate plus pentoxifylline. Int J Dermatol 2003, 42(3):203-207. 10.1046/j.1365-4362.2003.01868.x, 12653916.
38. Machado PR, Lessa H, Lessa M, Guimaraes LH, Bang H, Ho JL, Carvalho EM. Oral pentoxifylline combined with pentavalent antimony: a randomized trial for mucosal leishmaniasis. Clin Infect Dis 2007, 44(6):788-793. 10.1086/511643, 17304449.
39. Sadeghian G, Nilforoushzadeh MA. Effect of combination therapy with systemic glucantime and pentoxifylline in the treatment of cutaneous leishmaniasis. Int J Dermatol 2006, 45(7):819-821. 10.1111/j.1365-4632.2006.02867.x, 16863518.
40. Ives A, Ronet C, Prevel F, Ruzzante G, Fuertes-Marraco S, Schutz F, Zangger H, Revaz-Breton M, Lye LF, Hickerson SM, et al. Leishmania RNA virus controls the severity of mucocutaneous leishmaniasis. Science 2011, 331(6018):775-778. 10.1126/science.1199326, 3253482, 21311023.
41. Pirmez C, Yamamura M, Uyemura K, Paes-Oliveira M, Conceicao-Silva F, Modlin RL. Cytokine patterns in the pathogenesis of human leishmaniasis. J Clin Invest 1993, 91(4):1390-1395. 10.1172/JCI116341, 288111, 8473490.